Sanifit Therapeutics S.a.

Universitat De Les Illes Balears

Laboratorios Sanifit, S.l.

Other

Laboratoris Sanifit, S.l.

Numat Biomedical, S. L.

Joan Perello Bestard

Bernat Isern Amengual

Fernando Tur Espinosa

Carolina Salcedo Roca

Félix Grases Freixedas

Antonia Costa Bauza

Rafael M Prieto Almirall

Eva Martin Becerra

Paula Mendoza De Las Heras

Ciriaco Maraschiello De Zuani

Maximo Encabo Alarcon

Eva Tur Tur

Maria De Mar Benito Amengual

Irene Lentheric

Pilar Sanchis Cortes

Isabel Gomila Muñiz

Ana-Zeralda Canals Hamann

Miguel David Ferrer Reynes

Pieter H Joubert

Isabel Gomila Muniz

Felix Grases Freixedas

Marta Monjo Cabrer

Antonia Costa-Bauza

Rafael Mara Prieto Almirall

Ramon Garcia Gonzalez

Miquel David Ferrer Reynes

Joana Maria Ramis Morey

Maria Del Arriero Sanchez

Ruben Henriquez Palaez

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently —OH, —OP(O)(OH)2 or —P(O)(OH)2, with the proviso that at least two R are independently selected from —P(O)(OH)2 and —OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200

The present disclosure related to compositions, methods, dosages, dosage regimens, articles of manufacture and kits for the treatment and/or prevention ectopic calcifications, and in particular cutaneous calcifications such as calciphylaxis calcifications comprising inositol phosphate, inositol phosphate analogs, inositol phosphate derivatives, or combinations thereof. In a particular aspect the disclosure provides a dosage regimen to treat calciphylaxis comprising the administration of 6 mg/kg to 9 mg/kg daily doses of myo-inositol hexaphosphate, three times a week, for at least 1 to 8 months.

IP and IP analogs dosage regimens for the treatment of ectopic calcifications

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups R, wherein each R group means independently &#x2014;OH, &#x2014;OP(O)(OH)2 or &#x2014;P(O)(OH)2, with the proviso that at least two R are independently selected from &#x2014;P(O)(OH)2 and &#x2014;OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

Use of a derivative containing C&#x2014;O&#x2014;P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimimetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.

Use of derivatives containing C-O-P bonds in patients with kidney failure

The present invention relates to method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200, wherein the compound to be detected and/or quantified is a chemically complex molecule, wherein said chemically complex molecule is substituted with at least two groups &#x2014;R, wherein each R group means independently &#x2014;OH, &#x2014;OP(O)(OH)2 or &#x2014;P(O)(OH)2, with the proviso that at least two R are independently selected from &#x2014;P(O)(OH)2 and &#x2014;OP(O)(OH)2, wherein the compound or compounds to be detected and/or quantified are within a biological matrix, wherein said biological matrix is a biological fluid, a biological tissue, stomach contents, intestine contents, stool sample or a culture cells, wherein the method comprises performing a chromatography and identifying the retention time and/or the intensity of the signal by means of a mass or radioactivity detector.

Use of a derivative containing C&#x2014;O&#x2014;P bonds in a controlled release form to treat patients with kidney failure. Moreover, it comprises the use of said derivatives together with other active substances, which particularly may be selected from a list comprising a calcimirnetic, vitamin, phosphate binder, thiosulfate, bisphosphonate, pyrophosphate, citrate, diuretic, antihypertensive and anticholesteraemic agent.

Use of derivatives containing C&#x2014;O&#x2014;P bonds in patients with kidney failure

This invention relates to a composition that comprises inositol phosphates and/or bisphosphonates, and to the use thereof to prevent the loss of substances of biological interest in the body of patients subjected to dialysis and to maintain sufficient physiological levels of said substances to regulate physiological and/or pathological processes, these substances being inhibitors of pathological crystallization.

Composition of dialysis liquid comprising crystallisation inhibitor substances

The invention relates to a fixed-dose association of 5 phytate and zinc in synergic proportions for use in the treatment of crystallization of hydroxyapatite. Advantageously, said association is in a molar ratio between the phytate and the zinc exceeding 4:1. The invention also relates to the use of said 10 association for manufacturing a drug for the treatment, prophylaxis and/or prevention crystallization of hydroxyapatite in humans.

Fixed-dose association of phytate and zinc

The present invention relates to the use of myo-inositol hexaphosphate or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. These compounds may be utilized in the manufacture of functional foods, dietetic supplements, vitamin supplements, nutritional supplements, food supplements, or phytotherapeutic products having properties of inhibition of dissolution of crystals of calcium salts.

Use of phytate as agent inhibiting dissolution of crystals of calcium salts for the prevention of osteoporosis

Growing community of inventors

Palma De Mallorca, Spain

Joan Perello Bestard